These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 27673482)

  • 21. Enhancer Activity Requires CBP/P300 Bromodomain-Dependent Histone H3K27 Acetylation.
    Raisner R; Kharbanda S; Jin L; Jeng E; Chan E; Merchant M; Haverty PM; Bainer R; Cheung T; Arnott D; Flynn EM; Romero FA; Magnuson S; Gascoigne KE
    Cell Rep; 2018 Aug; 24(7):1722-1729. PubMed ID: 30110629
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Unique Approach to Design Potent and Selective Cyclic Adenosine Monophosphate Response Element Binding Protein, Binding Protein (CBP) Inhibitors.
    Bronner SM; Murray J; Romero FA; Lai KW; Tsui V; Cyr P; Beresini MH; de Leon Boenig G; Chen Z; Choo EF; Clark KR; Crawford TD; Jayaram H; Kaufman S; Li R; Li Y; Liao J; Liang X; Liu W; Ly J; Maher J; Wai J; Wang F; Zheng A; Zhu X; Magnuson S
    J Med Chem; 2017 Dec; 60(24):10151-10171. PubMed ID: 29155580
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bromodomain and histone acetyltransferase domain specificities control mixed lineage leukemia phenotype.
    Santillan DA; Theisler CM; Ryan AS; Popovic R; Stuart T; Zhou MM; Alkan S; Zeleznik-Le NJ
    Cancer Res; 2006 Oct; 66(20):10032-9. PubMed ID: 17047066
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses.
    Hammitzsch A; Tallant C; Fedorov O; O'Mahony A; Brennan PE; Hay DA; Martinez FO; Al-Mossawi MH; de Wit J; Vecellio M; Wells C; Wordsworth P; Müller S; Knapp S; Bowness P
    Proc Natl Acad Sci U S A; 2015 Aug; 112(34):10768-73. PubMed ID: 26261308
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design, synthesis, and biological evaluation of tetrahydroquinolin derivatives as potent inhibitors of CBP bromodomain.
    Chen Y; Bi X; Zhang F; Sun Z; Xu P; Jiang H; Lu W; Lu T; Ding H; Zhang N; Jiang H; Chen K; Zhou B; Luo C
    Bioorg Chem; 2020 Aug; 101():103991. PubMed ID: 32559581
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery and biological evaluation of thiobarbituric derivatives as potent p300/CBP inhibitors.
    Lu W; Xiong H; Chen Y; Wang C; Zhang H; Xu P; Han J; Xiao S; Ding H; Chen Z; Lu T; Wang J; Zhang Y; Yue L; Liu YC; Zhang C; Yang Y; Jiang H; Chen K; Zhou B; Luo C
    Bioorg Med Chem; 2018 Nov; 26(20):5397-5407. PubMed ID: 30297119
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery of Highly Potent, Selective, and Orally Efficacious p300/CBP Histone Acetyltransferases Inhibitors.
    Yang Y; Zhang R; Li Z; Mei L; Wan S; Ding H; Chen Z; Xing J; Feng H; Han J; Jiang H; Zheng M; Luo C; Zhou B
    J Med Chem; 2020 Feb; 63(3):1337-1360. PubMed ID: 31910017
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preclinical Safety Assessment of a Highly Selective and Potent Dual Small-Molecule Inhibitor of CBP/P300 in Rats and Dogs.
    Katavolos P; Cain G; Farman C; Romero FA; Magnuson S; Ly JQ; Choo EF; Katakam AK; Andaya R; Maher J
    Toxicol Pathol; 2020 Apr; 48(3):465-480. PubMed ID: 32124659
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design, synthesis and biological evaluation of a novel spiro oxazolidinedione as potent p300/CBP HAT inhibitor for the treatment of ovarian cancer.
    Ding H; Pei Y; Li Y; Xu W; Mei L; Hou Z; Guang Y; Cao L; Li P; Cao H; Bian J; Chen K; Luo C; Zhou B; Zhang T; Li Z; Yang Y
    Bioorg Med Chem; 2021 Dec; 52():116512. PubMed ID: 34801827
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery of Highly Potent and Efficient CBP/p300 Degraders with Strong
    Hu J; Xu H; Wu T; Zhang C; Shen H; Dong R; Hu Q; Xiang Q; Chai S; Luo G; Chen X; Huang Y; Zhao X; Peng C; Wu X; Lin B; Zhang Y; Xu Y
    J Med Chem; 2024 May; 67(9):6952-6986. PubMed ID: 38649304
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Structural basis of site-specific histone recognition by the bromodomains of human coactivators PCAF and CBP/p300.
    Zeng L; Zhang Q; Gerona-Navarro G; Moshkina N; Zhou MM
    Structure; 2008 Apr; 16(4):643-52. PubMed ID: 18400184
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design and synthesis of a biaryl series as inhibitors for the bromodomains of CBP/P300.
    Lai KW; Romero FA; Tsui V; Beresini MH; de Leon Boenig G; Bronner SM; Chen K; Chen Z; Choo EF; Crawford TD; Cyr P; Kaufman S; Li Y; Liao J; Liu W; Ly J; Murray J; Shen W; Wai J; Wang F; Zhu C; Zhu X; Magnuson S
    Bioorg Med Chem Lett; 2018 Jan; 28(1):15-23. PubMed ID: 29169673
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Angiotensinogen gene expression is dependent on signal transducer and activator of transcription 3-mediated p300/cAMP response element binding protein-binding protein coactivator recruitment and histone acetyltransferase activity.
    Ray S; Sherman CT; Lu M; Brasier AR
    Mol Endocrinol; 2002 Apr; 16(4):824-36. PubMed ID: 11923478
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discovery of novel nucleoside derivatives as selective lysine acetyltransferase p300 inhibitors for cancer therapy.
    Dai Q; Yuan Z; Sun Q; Ao Z; He B; Jiang Y
    Bioorg Med Chem Lett; 2024 May; 104():129742. PubMed ID: 38604299
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Time-Resolved Analysis Reveals Rapid Dynamics and Broad Scope of the CBP/p300 Acetylome.
    Weinert BT; Narita T; Satpathy S; Srinivasan B; Hansen BK; Schölz C; Hamilton WB; Zucconi BE; Wang WW; Liu WR; Brickman JM; Kesicki EA; Lai A; Bromberg KD; Cole PA; Choudhary C
    Cell; 2018 Jun; 174(1):231-244.e12. PubMed ID: 29804834
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structure of the p300 histone acetyltransferase bound to acetyl-coenzyme A and its analogues.
    Maksimoska J; Segura-Peña D; Cole PA; Marmorstein R
    Biochemistry; 2014 Jun; 53(21):3415-22. PubMed ID: 24819397
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery of Novel PROTAC Degraders of p300/CBP as Potential Therapeutics for Hepatocellular Carcinoma.
    Chang Q; Li J; Deng Y; Zhou R; Wang B; Wang Y; Zhang M; Huang X; Li Y
    J Med Chem; 2024 Feb; 67(4):2466-2486. PubMed ID: 38316017
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bromodomain inhibition of the coactivators CBP/EP300 facilitate cellular reprogramming.
    Ebrahimi A; Sevinç K; Gürhan Sevinç G; Cribbs AP; Philpott M; Uyulur F; Morova T; Dunford JE; Göklemez S; Arı Ş; Oppermann U; Önder TT
    Nat Chem Biol; 2019 May; 15(5):519-528. PubMed ID: 30962627
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Probing the reaction coordinate of the p300/CBP histone acetyltransferase with bisubstrate analogs.
    Karukurichi KR; Cole PA
    Bioorg Chem; 2011 Feb; 39(1):42-7. PubMed ID: 21111442
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Early Drug-Discovery Efforts towards the Identification of EP300/CBP Histone Acetyltransferase (HAT) Inhibitors.
    Huhn AJ; Gardberg AS; Poy F; Brucelle F; Vivat V; Cantone N; Patel G; Patel C; Cummings R; Sims R; Levell J; Audia JE; Bommi-Reddy A; Wilson JE
    ChemMedChem; 2020 Jun; 15(11):955-960. PubMed ID: 32181984
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.